Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business of Psychedelics, Bitcoin Post published:May 2, 2025 Post category:Psychedelic Bulletin/Pα+
March & April 2025 Psychedelic Patent Update: Lykos’ Patent Woes Continue; Filings Provide First Look at Seaport’s 2-Bromo-LSD Program; Delix’s Ergoline Analogues; CaaMTech’s Spinout Post published:May 1, 2025 Post category:Psychedelic Patent Analysis/Pα+
Pα+ Psychedelic Bulletin #194: Make-or-Break Moment Looms for Compass; RFK Jr. Discusses LSD Use; Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona Post published:April 25, 2025 Post category:Psychedelic Bulletin/Pα+
Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride Post published:April 18, 2025 Post category:Interviews/Pα+
Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability of Psilocybin’s Persistent Effects in Mice; Market Mayhem and Agency Shake-Ups Post published:April 11, 2025 Post category:Psychedelic Bulletin/Pα+
Psychedelic Policy Update: Medical Access, Industry Influence, and Voter Suppression Shape 2025 Landscape Post published:April 9, 2025 Post category:Analysis/News/Pα+
March 2025’s Psychedelic Policy Momentum: New Bills Filed Across the U.S. as Nearly 30 States Deliberate Reforms Post published:April 7, 2025 Post category:Analysis/News/Pα+
Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program Post published:March 31, 2025 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD Microdosing No Better than Placebo in ADHD Post published:March 28, 2025 Post category:Psychedelic Bulletin/Pα+